Selected characteristics of the study population by cohort (Pooled, ATBC, and HPFS)
| . | Pooled . | ATBC31 . | HPFS30 . | |||
|---|---|---|---|---|---|---|
| Cases . | Controls . | Cases . | Controls . | Cases . | Controls . | |
| No. of persons | 493 | 978 | 46 | 92 | 29 | 58 |
| Mean age at blood draw, y (SD) | 63.3 (7.1) | 63.3 (7.2) | 58.6 (4.7) | 58.5 (4.7) | 62.7 (9.4) | 62.6 (9.5) |
| Sex, N (%) | ||||||
| Male | 172 (34.9) | 344 (35.2) | 46 (100) | 92 (100) | 29 (100) | 58 (100) |
| Female | 321 (65.1) | 634 (64.8) | NA | NA | NA | NA |
| Race, N (%) | ||||||
| White | 432 (87.6) | 860 (87.9) | 46 (100) | 92 (100) | 26 (89.7) | 55 (94.8) |
| Black | 32 (6.5) | 62 (5.3) | NA | NA | 1 (3.5) | NA |
| Asian | 12 (2.4) | 25 (2.6) | NA | NA | NA | NA |
| Other | 17 (3.4) | 31 (3.2) | NA | NA | 2 (6.9) | 3 (5.2) |
| Mean BMI at blood draw, kg/m2 (SD) | 27.4 (5.2) | 27.2 (5.0) | 26.7 (2.8) | 26.2 (3.8) | 26.3 (3.3) | 26.0 (3.2) |
| < 18.5, N (%) | 2 (0.4) | 8 (0.8) | NA | NA | 9 (31.0) | 24 (41.4) |
| < 18.5-25, N (%) | 163 (33.1) | 342 (35.0) | 10 (21.7) | 37 (40.2) | 15 (51.7) | 27 (46.6) |
| < 25-30, N (%) | 215 (43.6) | 406 (41.5) | 29 (63.0) | 42 (45.7) | 4 (13.8) | 4 (6.9) |
| 30+, N (%) | 110 (22.3) | 212 (21.7) | 7 (15.2) | 13 (14.1) | 1 (3.5) | 3 (5.2) |
| Missing, N (%) | 3 (0.6) | 10 (1.0) | NA | NA | NA | NA |
| Type of blood sample, N (%) | ||||||
| Serum | 70 (14.2) | 140 (14.3) | 46 (100) | 92 (100) | NA | NA |
| Plasma, heparin | 200 (40.6) | 392 (40.1) | NA | NA | NA | NA |
| Plasma, EDTA | 202 (41.0) | 404 (41.3) | NA | NA | 29 (100) | 58 (100) |
| Plasma, sodium citrate | 21 (4.3) | 42 (4.3) | NA | NA | NA | NA |
| Fasting status, N (%) | ||||||
| Fasting | 354 (71.8) | 709 (72.5) | 39 (84.8) | 78 (84.8) | 21 (72.4) | 42 (72.4) |
| Not fasting | 139 (28.2) | 269 (27.5) | 7 (15.2) | 14 (15.2) | 8 (27.6) | 16 (27.6) |
| Mean blood draw to diagnosis, y (range) | 6.6 (0.3-18.1) | 6.5 (−0.5 to 18.2) | 9.8 (1.3-18.1) | 9.8 (1.3-18.2) | 6.6 (0.5-12.2) | 6.6 (0.4-12.3) |
| ≤ 3, N (%) | 92 (18.7) | 170 (17.9) | 4 (8.7) | 8 (8.7) | 8 (28.6) | 15 (27.3) |
| 4- ≤ 6, N (%) | 150 (30.6) | 303 (31.8) | 10 (21.7) | 18 (19.6) | 5 (17.9) | 10 (18.2) |
| > 6, N (%) | 249 (50.7) | 479 (50.3) | 32 (69.6) | 66 (71.7) | 15 (53.6) | 30 (54.6) |
| Mean peripheral blood biomarker concentrations (SD) | ||||||
| IGF-1, ng/mL | 150 (52.5) | 146.4 (49.4) | 170.3 (38.7) | 150.9 (44.5) | 189.6 (49.2) | 168.8 (46.2) |
| IGFBP-3, ng/mL | 4490 (1203) | 4423 (1170) | 3859 (941) | 3402 (1053) | 4531 (1110) | 4267 (991) |
| IGF-1/IGFBP-3 molar ratio | 0.1 (0.03) | 0.1 (0.03) | 0.2 (0.04) | 0.2 (0.03) | 0.2 (0.03) | 0.1 (0.02) |
| IGFBP-1, ng/mL | 32.2 (24.9) | 30.3 (32.3) | 21.9 (14.9) | 25.2 (14.7) | 34.9 (29.5) | 28.8 (19.9) |
| C-peptide, ng/mL | 2.1 (1.5) | 2.1 (1.6) | 1.9 (0.8) | 1.7 (1.1) | 2.4 (1.1) | 2.6 (1.6) |
| CRP, mg/L | 3.5 (5.6) | 3.7 (5.8) | 4.1 (6.8) | 4.2 (8.3) | 1.7 (1.6) | 1.3(1.4) |
| IL-6, pg/mL | 2.2 (2.3) | 2.5 (4.5) | 3.0 (2.9) | 3.7 (5.5) | 1.7 (1.5) | 1.5 (1.2) |
| sIL6R, pg/mL | 41 871 (15 713) | 39 278 (10 923) | 36 502 (9674) | 36 318 (8881) | 43 084 (15 111) | 36 087 (8244) |
| . | Pooled . | ATBC31 . | HPFS30 . | |||
|---|---|---|---|---|---|---|
| Cases . | Controls . | Cases . | Controls . | Cases . | Controls . | |
| No. of persons | 493 | 978 | 46 | 92 | 29 | 58 |
| Mean age at blood draw, y (SD) | 63.3 (7.1) | 63.3 (7.2) | 58.6 (4.7) | 58.5 (4.7) | 62.7 (9.4) | 62.6 (9.5) |
| Sex, N (%) | ||||||
| Male | 172 (34.9) | 344 (35.2) | 46 (100) | 92 (100) | 29 (100) | 58 (100) |
| Female | 321 (65.1) | 634 (64.8) | NA | NA | NA | NA |
| Race, N (%) | ||||||
| White | 432 (87.6) | 860 (87.9) | 46 (100) | 92 (100) | 26 (89.7) | 55 (94.8) |
| Black | 32 (6.5) | 62 (5.3) | NA | NA | 1 (3.5) | NA |
| Asian | 12 (2.4) | 25 (2.6) | NA | NA | NA | NA |
| Other | 17 (3.4) | 31 (3.2) | NA | NA | 2 (6.9) | 3 (5.2) |
| Mean BMI at blood draw, kg/m2 (SD) | 27.4 (5.2) | 27.2 (5.0) | 26.7 (2.8) | 26.2 (3.8) | 26.3 (3.3) | 26.0 (3.2) |
| < 18.5, N (%) | 2 (0.4) | 8 (0.8) | NA | NA | 9 (31.0) | 24 (41.4) |
| < 18.5-25, N (%) | 163 (33.1) | 342 (35.0) | 10 (21.7) | 37 (40.2) | 15 (51.7) | 27 (46.6) |
| < 25-30, N (%) | 215 (43.6) | 406 (41.5) | 29 (63.0) | 42 (45.7) | 4 (13.8) | 4 (6.9) |
| 30+, N (%) | 110 (22.3) | 212 (21.7) | 7 (15.2) | 13 (14.1) | 1 (3.5) | 3 (5.2) |
| Missing, N (%) | 3 (0.6) | 10 (1.0) | NA | NA | NA | NA |
| Type of blood sample, N (%) | ||||||
| Serum | 70 (14.2) | 140 (14.3) | 46 (100) | 92 (100) | NA | NA |
| Plasma, heparin | 200 (40.6) | 392 (40.1) | NA | NA | NA | NA |
| Plasma, EDTA | 202 (41.0) | 404 (41.3) | NA | NA | 29 (100) | 58 (100) |
| Plasma, sodium citrate | 21 (4.3) | 42 (4.3) | NA | NA | NA | NA |
| Fasting status, N (%) | ||||||
| Fasting | 354 (71.8) | 709 (72.5) | 39 (84.8) | 78 (84.8) | 21 (72.4) | 42 (72.4) |
| Not fasting | 139 (28.2) | 269 (27.5) | 7 (15.2) | 14 (15.2) | 8 (27.6) | 16 (27.6) |
| Mean blood draw to diagnosis, y (range) | 6.6 (0.3-18.1) | 6.5 (−0.5 to 18.2) | 9.8 (1.3-18.1) | 9.8 (1.3-18.2) | 6.6 (0.5-12.2) | 6.6 (0.4-12.3) |
| ≤ 3, N (%) | 92 (18.7) | 170 (17.9) | 4 (8.7) | 8 (8.7) | 8 (28.6) | 15 (27.3) |
| 4- ≤ 6, N (%) | 150 (30.6) | 303 (31.8) | 10 (21.7) | 18 (19.6) | 5 (17.9) | 10 (18.2) |
| > 6, N (%) | 249 (50.7) | 479 (50.3) | 32 (69.6) | 66 (71.7) | 15 (53.6) | 30 (54.6) |
| Mean peripheral blood biomarker concentrations (SD) | ||||||
| IGF-1, ng/mL | 150 (52.5) | 146.4 (49.4) | 170.3 (38.7) | 150.9 (44.5) | 189.6 (49.2) | 168.8 (46.2) |
| IGFBP-3, ng/mL | 4490 (1203) | 4423 (1170) | 3859 (941) | 3402 (1053) | 4531 (1110) | 4267 (991) |
| IGF-1/IGFBP-3 molar ratio | 0.1 (0.03) | 0.1 (0.03) | 0.2 (0.04) | 0.2 (0.03) | 0.2 (0.03) | 0.1 (0.02) |
| IGFBP-1, ng/mL | 32.2 (24.9) | 30.3 (32.3) | 21.9 (14.9) | 25.2 (14.7) | 34.9 (29.5) | 28.8 (19.9) |
| C-peptide, ng/mL | 2.1 (1.5) | 2.1 (1.6) | 1.9 (0.8) | 1.7 (1.1) | 2.4 (1.1) | 2.6 (1.6) |
| CRP, mg/L | 3.5 (5.6) | 3.7 (5.8) | 4.1 (6.8) | 4.2 (8.3) | 1.7 (1.6) | 1.3(1.4) |
| IL-6, pg/mL | 2.2 (2.3) | 2.5 (4.5) | 3.0 (2.9) | 3.7 (5.5) | 1.7 (1.5) | 1.5 (1.2) |
| sIL6R, pg/mL | 41 871 (15 713) | 39 278 (10 923) | 36 502 (9674) | 36 318 (8881) | 43 084 (15 111) | 36 087 (8244) |
Percentages and counts may not sum to the total because of rounding and/or missing data.
NA indicates not applicable.